Wockhardt reported a positive Profit Before Tax (PBT) of INR 91 crore for Q2FY26, reversing a previous loss. Revenue reached INR 782 Cr. This quarter saw 22% revenue contribution from innovative portfolios. The company also highlighted key developments in its antibiotic and biosimilar programs, including regulatory submissions and clinical advancements, signifying a robust growth trajectory.
Financial Performance Highlights
Wockhardt Limited announced its Q2FY26 results, showcasing a significant turnaround with a Profit Before Tax (PBT) of INR 91 crore. This is a marked improvement compared to the previous quarter’s loss. Revenue for Q2FY26 stood at INR 782 Cr, compared to INR 738 Cr in the previous quarter.
EBITDA for Q2FY26 reached INR 160 Cr, a 58% QoQ growth from INR 101 Cr in the previous quarter. Innovative portfolio contributions accounted for 22% of the revenue in Q2FY26 and 19% in H1 FY26.
Novel Antibiotics Program
The company made a New Drug Application (NDA) submission to the U.S. FDA in September 2025 for its novel antibacterial agent ZAYNICH, aimed at treating complicated urinary tract infections. Saudi FDA granted Breakthrough designation in July ’25.
MIQNAF (Nafithromycin), approved and launched on May 27, 2025, saw its Phase 3 CABP study published in the LANCET journal, ranking 10th among 185 journals in Health Care Sciences.
Other Key Developments
Emrok and Emrok O are included in Clinical Infectious Disease Society’s treatment guidelines 2025. A Fast Track designation by USFDA was granted to Ertapenem-Zidebactam (WCK 6777).
Biosimilar Business Growth
The overall Biotech operations for the quarter stood at INR 154 Crores, a 42% growth compared to Q4 FY25, and 41% growth from Q1 FY26. Emerging market biotech segment growth exceeded 50%.
New Product Launches and Approvals
Wockhardt reported 2 filings and 7 launches in Wockhardt UK, with 2 filings and 6 launches in Pinewood. The company also has 7 Biosimilars filings and 10 approvals and NCE 2 filings & 1 approval. Registration for EMROK/ EMROK O has been filed in 9 countries.
Approval was also received for EMROK O for Uganda and for EMROK injection in August 2025.
Intellectual Property
7 patents were filed during the quarter ended September 30th 2025, bringing the cumulative filings to 3285. The company was granted 5 patents, holding 858 patents in total.
Source: BSE
